Download presentation
Presentation is loading. Please wait.
Published byPierre-Louis Fleury Modified over 6 years ago
1
Soluble Receptor for Advanced Glycation End Products Quantifies Lung Injury in Polytraumatized Patients Lukas L. Negrin, MD, MSc, Gabriel Halat, MD, Helmut Prosch, MD, Michael Hüpfl, MD, Stefan Hajdu, MD, MBA, Thomas Heinz, MD The Annals of Thoracic Surgery Volume 103, Issue 5, Pages (May 2017) DOI: /j.athoracsur Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
2
Fig 1 (A) Defined regions of interest (ROI) in the lung window of an axial computed tomographic (CT) image: contusion areas (left) and lung borders (right) of a right lung. (B) Visualization of the entire pathology in a 3-dimensional model of the corresponding lung (parenchymal lung injury [PLI] in blue, lung in turquoise) displayed in anteroposterior, lateral, and oblique views. The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
3
Fig 2 Box plots displaying the distribution of (A) initial soluble receptor for advanced glycation end products (sRAGE) and (B) club cell protein (CC16), which depended on the incidence of parenchymal lung injury (PLI). The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
4
Fig 3 (A) Box plot displaying the distribution of initial soluble receptor for advanced glycation end products (sRAGE), depending on the manifestation of parenchymal lung injury (PLI). (B) ROC curve analysis for initial sRAGE level as a predictor of severe PL. The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.